189 related articles for article (PubMed ID: 28070720)
1. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
Saka H; Kitagawa C; Kogure Y; Takahashi Y; Fujikawa K; Sagawa T; Iwasa S; Takahashi N; Fukao T; Tchinou C; Landers D; Yamada Y
Invest New Drugs; 2017 Aug; 35(4):451-462. PubMed ID: 28070720
[TBL] [Abstract][Full Text] [Related]
2. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
Yamamoto N; Ryoo BY; Keam B; Kudo M; Lin CC; Kunieda F; Ball HA; Moran D; Komatsu K; Takeda K; Fukuda M; Furuse J; Morita S; Doi T
Invest New Drugs; 2020 Apr; 38(2):445-456. PubMed ID: 31041575
[TBL] [Abstract][Full Text] [Related]
4. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Paik PK; Shen R; Berger MF; Ferry D; Soria JC; Mathewson A; Rooney C; Smith NR; Cullberg M; Kilgour E; Landers D; Frewer P; Brooks N; André F
Clin Cancer Res; 2017 Sep; 23(18):5366-5373. PubMed ID: 28615371
[No Abstract] [Full Text] [Related]
5. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
[TBL] [Abstract][Full Text] [Related]
7. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
Cancer Chemother Pharmacol; 2016 May; 77(5):997-1003. PubMed ID: 27025608
[TBL] [Abstract][Full Text] [Related]
8. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring
Voss MH; Hierro C; Heist RS; Cleary JM; Meric-Bernstam F; Tabernero J; Janku F; Gandhi L; Iafrate AJ; Borger DR; Ishii N; Hu Y; Kirpicheva Y; Nicolas-Metral V; Pokorska-Bocci A; Vaslin Chessex A; Zanna C; Flaherty KT; Baselga J
Clin Cancer Res; 2019 May; 25(9):2699-2707. PubMed ID: 30745300
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
[TBL] [Abstract][Full Text] [Related]
11. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
Tabernero J; Bahleda R; Dienstmann R; Infante JR; Mita A; Italiano A; Calvo E; Moreno V; Adamo B; Gazzah A; Zhong B; Platero SJ; Smit JW; Stuyckens K; Chatterjee-Kishore M; Rodon J; Peddareddigari V; Luo FR; Soria JC
J Clin Oncol; 2015 Oct; 33(30):3401-8. PubMed ID: 26324363
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Lam WS; Creaney J; Chen FK; Chin WL; Muruganandan S; Arunachalam S; Attia MS; Read C; Murray K; Millward M; Spiro J; Chakera A; Gary Lee YC; Nowak AK
Lung Cancer; 2020 Feb; 140():87-92. PubMed ID: 31901768
[TBL] [Abstract][Full Text] [Related]
13. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Yonemori K; Tamura K; Kodaira M; Fujikawa K; Sagawa T; Esaki T; Shirakawa T; Hirai F; Yokoi Y; Kawata T; Hatano B; Takahashi Y
Cancer Chemother Pharmacol; 2016 Sep; 78(3):525-31. PubMed ID: 27422301
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
17. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Chae YK; Hong F; Vaklavas C; Cheng HH; Hammerman P; Mitchell EP; Zwiebel JA; Ivy SP; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Mansfield A; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Jul; 38(21):2407-2417. PubMed ID: 32463741
[TBL] [Abstract][Full Text] [Related]
19. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Nogova L; Sequist LV; Perez Garcia JM; Andre F; Delord JP; Hidalgo M; Schellens JH; Cassier PA; Camidge DR; Schuler M; Vaishampayan U; Burris H; Tian GG; Campone M; Wainberg ZA; Lim WT; LoRusso P; Shapiro GI; Parker K; Chen X; Choudhury S; Ringeisen F; Graus-Porta D; Porter D; Isaacs R; Buettner R; Wolf J
J Clin Oncol; 2017 Jan; 35(2):157-165. PubMed ID: 27870574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
